申请人:Banyu Pharmaceutical Co., Ltd.
公开号:US07960394B2
公开(公告)日:2011-06-14
This invention provides a compound or its pharmaceutically-acceptable salt of formula (I)
wherein R1 represents a lower alkyl group et al; R2 and R3 are same and different and represents hydrogen atm et al; R4 represents the substituent of the formula (II) et al;
X1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.
本发明提供了式(I)的化合物或其药学上可接受的盐,其中R1代表低碳基等;R2和R3相同或不同,代表氢原子等;R4代表式(II)的取代基等;X1代表NH、O或S;Y代表N或C;Ar是从芳基中派生的双价取代基等,通过从中去除两个氢原子;环A代表一个5-或6-成员杂芳基团;这些化合物具有组织胺H3受体拮抗作用或组织胺H3受体反向激动剂作用,并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。